Imaging plays a vital role in the diagnosis and management of rheumatological disorders. Traditionally, plain film radiography was widely used in arthropathies to assess periarticular bony changes; these often reflect established changes in the late stage of disease and thus have limited value in early diagnosis and disease monitoring. Magnetic resonance imaging (MRI) has become an important imaging modality in rheumatological disorders because it can assess both morphological and functional changes. It plays a substantial role in early diagnosis, monitoring of disease evolution, assessment of treatment responses and prognostication. More recently, advances in hardware and novel imaging sequences have aided the development of new MRI techniques: whole-body MRI, for example, is gaining in popularity and allows an assessment of overall inflammatory status in arthritis. Quantitative MRI shows promise in allowing more objective evaluation and standardization of imaging-based assessment of inflammatory arthritis. This article also discusses other emerging imaging techniques. These include high-resolution peripheral quantitative computed tomography in early detection and monitoring of periarticular bone damage, fluorescence optical imaging in visualizing active inflammation, and molecular imaging in investigating pathogenesis and disease evaluation on a cellular level.
Introduction
Plain radiography has in the past been the primary imaging tool for investigating arthropathies. Radiographic features of the various types of arthritis have been extensively described in the literature and previously in this journal. However, structural bony changes, such as sclerosis and erosions, seen on radiographs, occur late in the course of disease, and early changes are not apparent. The sensitivity of plain films is low, and disease activity cannot be adequately assessed. Pelvic and lumbar spine radiography incurs a relatively high dose of ionizing radiation; for example, the dose from an anteroposterior radiograph of the pelvis is 35 times that from a chest X-ray. It should therefore be avoided where possible, particularly in children and adolescents. Magnetic resonance imaging (MRI) and ultrasonography are being increasingly used to aid early diagnosis of arthropathies, and this facilitates early treatment that may prevent progression to irreversible structural damage.
Here we describe recent advances in the imaging of rheumatological diseases. For a more in-depth review of the role of ultrasound, the interested reader is referred to the dedicated ultrasound chapter (10.1016/j.mpmed.2017.12.010) in this publication.
Magnetic resonance imaging
MRI has emerged as the most sensitive imaging modality for detecting arthritis and discriminating between acute and chronic inflammation. In recent years, substantial technical advances have been made in software and hardware, such as phased-array coils, higher performance gradients, parallel imaging and advanced post-processing techniques. This has led to reduced scan times and improved image quality.
Other advances include isotropic three-dimensional (3D) imaging techniques, which reduce partial volume artefacts and allow reformatting in multiple planes for improved visualization of anatomy and pathology. High-field strength systems (e.g. 3T MRI) are increasingly used in clinical practice, providing better spatial resolution and signal-to-noise ratio. Applications of morphological MRI and common findings Conventionally, morphological and contrast-enhanced MRI are used to assess inflammatory arthritis. In general, short tau inversion recovery (STIR) and contrast-enhanced T1-weighted images are useful for assessing active inflammation.
In rheumatoid arthritis, the diseased joints show proliferative synovitis on MRI. This inflammation leads to bone erosions, which in the acute phase demonstrate loss of cortical definition and presence of subcortical bone marrow oedema (osteitis). These are seen as high signal on STIR (which is fluid-sensitive) and contrast-enhanced images. Mature erosions show sharply marginated areas of trabecular bone loss with cortical defects.
Tenosynovitis, a common finding, is seen as synovial sheath thickening with marked enhancement on post-contrast images.
In axial and peripheral spondyloarthropathies, sacroiliitis is a common feature; it is seen on MRI as subchondral bone marrow oedema, synovitis, capsulitis and enthesitis. In the new Assessment of Spondyloarthritis International Society criteria for axial spondyloarthritis, 1 the presence of subchondral bone marrow oedema is mandatory for the diagnosis of acute sacroiliitis. In chronic sacroiliitis, periarticular fat metaplasia, sclerosis and erosions are seen, followed by ankylosis in some patients. Active spondylitis is seen as facet and costovertebral joint synovitis, enthesitis of spinal ligaments and corner inflammatory lesions resulting from bone marrow oedema of the vertebral entheses. (Figure 2) , and have been used to evaluate sacroiliitis and as a biomarker for measuring treatment response. 4 DCE-MRI uses serial imaging at short intervals (typically a few seconds) during intravenous contrast administration. The dynamic enhancement profiles (time versus signal intensity) of the diseased region differ from those of normal tissue because of the presence of inflammation and neoangiogenesis; they have been shown to correlate with disease activity and predict progression of erosive disease.
5 It is also possible to derive quantitative physiological parameters by fitting dynamic enhancement data to pharmacokinetic models, which reflect exchanges between plasma and extracellular extravascular space. Such absolute parameters have the advantage of being independent of MRI hardware and parameters, and have shown promise for detecting synovial inflammation in early arthritis and assessment of tissue microcirculation. CSE-MRI uses the small difference between the precession frequencies of water and fat protons when exposed to a strong external magnetic field (i.e. inside an MRI scanner). This phenomenon allows quantitative measurement of water and fat composition, and by the same token bone marrow oedema and fat metaplasia, which reflect active inflammation and structural damage, respectively, in inflammatory arthritis (Figure 3 ). This technique has been successfully applied in a cohort of adolescent patients with sacroiliitis to quantify bone inflammation and healing. 
Other novel imaging modalities
Outside MRI, a number of novel imaging modalities for evaluating rheumatological disorders have emerged in recent years, including the following.
Fluorescence optical imaging (FOI): this involves intravenous administration of a non-specific fluorophore (typically indocyanine green), which is excited by light at the dark red spectrum. The emitting fluorescence is detected by an optical camera sensor and imaged serially every second over a few minutes. Active inflammation is seen as increased fluorescence intensity caused by increased neovascularity. FOI allows a quick overview of active inflammation, and has the potential to detect subclinical inflammation that is not apparent on clinical examination or ultrasound. Unlike ultrasound, it has the advantage of being operator-independent, but it is currently limited to evaluating the hand and wrist, and does not provide morphological information.
High-resolution peripheral quantitative computed tomography (HR-pQCT): HR-pQCT offers extremely high-resolution 3D imaging (typically 82-micrometre isotropic voxel size) of bone structure with a low radiation dose. The high resolution and quantitative nature of this technique enable assessment of periarticular bone marrow density and cortical/trabecular microarchitecture for detecting early erosive damage.
Molecular imaging: the imaging modalities discussed so far e albeit with great promises and advances e rely on the detection of anatomical and structural changes related to the disease, and are insensitive to the preceding molecular and cellular changes in the very early stages of pathogenesis. 'Molecular imaging' is a collective term used to describe techniques that employ molecular probes to allow visualization of the underlying biochemical processes driving the disease.
Probes are designed to target various disease processes such as inflammation, T/B cell activation, activated macrophages, activated vascular endothelium and apoptosis. To visualize these processes, probes are bound to imaging tracers (typically radiolabelled, which facilitate detection through tissue penetration) that are detected using modalities such as positron-emission tomography CT and single photon emission CT.
Molecular imaging has also shown great potential in the development of personalized therapy; for example, the use radiolabelled biologicals such as anti-tumour necrosis factor-a and anti-CD20 allows confirmation of the presence of these targets in a patient; this may help in predicting and selecting the most efficacious treatment. aging is a sensitive biomarker of response to biologic therapy in enthesitis-related arthritis. Rheumato (Oxford) 2017; 56: 399e407. 5 Huang J, Stewart N, Crabbe J, et al. A 1-year follow-up study of dynamic magnetic resonance imaging in early rheumatoid arthritis reveals synovitis to be increased in shared epitope-positive Figure 3 Chemical-shift encoding MRI in spondyloarthritis: fat fraction (FF) and R2* images showing areas of bone marrow oedema (solid arrows) versus fat metaplasia (dash arrows). R2* represents the rate of transverse magnetization decay, and has been proposed as a marker for bone mineral loss/osteoporosis. FF values are reduced in areas of bone marrow oedema (a), but increased in areas of fat metaplasia (b). R2* measurements are slightly reduced in areas of bone marrow oedema (c) and markedly reduced in areas of fat metaplasia (d), which may be due to local osteoporosis. Image courtesy of Dr TJP Bray, UCLH, London.
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